EA201690376A1 - Ингибиторы дезоксицитидинкиназы - Google Patents

Ингибиторы дезоксицитидинкиназы

Info

Publication number
EA201690376A1
EA201690376A1 EA201690376A EA201690376A EA201690376A1 EA 201690376 A1 EA201690376 A1 EA 201690376A1 EA 201690376 A EA201690376 A EA 201690376A EA 201690376 A EA201690376 A EA 201690376A EA 201690376 A1 EA201690376 A1 EA 201690376A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
compounds
deoxicitidinkinase
cancer
dck
Prior art date
Application number
EA201690376A
Other languages
English (en)
Other versions
EA036177B1 (ru
Inventor
Каюс Г. Раду
Чжэн Ли
Рэймонд М. Гипсон
Дзуе Ван
Нагихеттиар Сатиамурти
Арнон Лави
Дженнифер М. Мерфи
Девид А. Натансон
Майкл Е. Джунг
Original Assignee
Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния, Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Иллинойс filed Critical Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния
Publication of EA201690376A1 publication Critical patent/EA201690376A1/ru
Publication of EA036177B1 publication Critical patent/EA036177B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Abstract

В данном документе представлены соединения, которые связывают dCK, и способы лечения рака. Более конкретно, производные 2-фенилтиазола, связанные с 4,6-диаминопиримидиновым фрагментом, раскрыты как ингибиторы активности дезоксицитидинкиназы. Кроме того, представлены ингибиторы - соединения, имеющие стереоцентр. Данные соединения имеют терапевтическое применение в лечении рака.
EA201690376A 2013-08-13 2014-08-13 Ингибиторы дезоксицитидинкиназы EA036177B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361865468P 2013-08-13 2013-08-13
PCT/US2014/050931 WO2015023776A2 (en) 2013-08-13 2014-08-13 Deoxycytidine kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201690376A1 true EA201690376A1 (ru) 2016-07-29
EA036177B1 EA036177B1 (ru) 2020-10-09

Family

ID=52468801

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690376A EA036177B1 (ru) 2013-08-13 2014-08-13 Ингибиторы дезоксицитидинкиназы

Country Status (11)

Country Link
US (2) US9598404B2 (ru)
EP (1) EP3033340B1 (ru)
JP (1) JP6542216B2 (ru)
KR (1) KR102330566B1 (ru)
CN (1) CN105658648B (ru)
AU (1) AU2014306673B2 (ru)
BR (1) BR112016003019A2 (ru)
CA (1) CA2920738A1 (ru)
EA (1) EA036177B1 (ru)
IL (1) IL244029B (ru)
WO (1) WO2015023776A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3033340B1 (en) * 2013-08-13 2019-12-04 The Regents of The University of California Deoxycytidine kinase inhibitors
CA3010723A1 (en) * 2016-01-08 2017-07-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds
CN106421790B (zh) * 2016-11-25 2018-12-25 复旦大学附属金山医院 Cmpk的抑制剂在制备治疗卵巢癌的药物中的应用
CN109134354B (zh) * 2018-09-19 2022-03-25 天津科技大学 2-吡啶甲基硫醚的合成方法及相关药物的合成工艺
US20220133735A1 (en) 2020-11-02 2022-05-05 Trethera Corporation Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014657A1 (en) * 2006-07-12 2008-01-17 Beckton Dickinson And Company Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device
US8093246B2 (en) * 2006-12-14 2012-01-10 Lexicon Pharmaceuticals, Inc. O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer
JP2012531435A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体
BR112013020329A2 (pt) * 2011-02-09 2016-08-02 Hoffmann La Roche compostos heterocíclicos como inibidores da pi3-quinase
WO2012122368A1 (en) * 2011-03-08 2012-09-13 The Regents Of The University Of California Deoxycytidine kinase binding compounds
EP2518071A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) * 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
EP3033340B1 (en) * 2013-08-13 2019-12-04 The Regents of The University of California Deoxycytidine kinase inhibitors

Also Published As

Publication number Publication date
KR102330566B1 (ko) 2021-11-25
EP3033340A4 (en) 2017-01-25
EP3033340A2 (en) 2016-06-22
AU2014306673B2 (en) 2018-12-06
EA036177B1 (ru) 2020-10-09
BR112016003019A2 (pt) 2017-09-12
JP2016530266A (ja) 2016-09-29
KR20160058785A (ko) 2016-05-25
CN105658648A (zh) 2016-06-08
WO2015023776A2 (en) 2015-02-19
JP6542216B2 (ja) 2019-07-10
IL244029B (en) 2019-10-31
CN105658648B (zh) 2020-03-17
CA2920738A1 (en) 2015-02-19
US9981961B2 (en) 2018-05-29
WO2015023776A3 (en) 2015-11-12
US20160237076A1 (en) 2016-08-18
US20170204090A1 (en) 2017-07-20
US9598404B2 (en) 2017-03-21
IL244029A0 (en) 2016-04-21
EP3033340B1 (en) 2019-12-04
AU2014306673A1 (en) 2016-03-03

Similar Documents

Publication Publication Date Title
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201890754A1 (ru) Соединения и способы их применения
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
MX362215B (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201590997A1 (ru) Соединения и способы их применения
EA201690206A1 (ru) Терапевтически активные соединения и способы их применения
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
EA201591509A1 (ru) Ингибиторы cdc7
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
PH12017500215A1 (en) Protein kinase c inhibitors and methods of their use
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2016009663A (es) Derivados de icariina.
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
EA201690376A1 (ru) Ингибиторы дезоксицитидинкиназы
EA201791933A1 (ru) Ингибирование активности olig2

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM